The role of palliative radiotherapy in the management of elderly and frail patients with advanced bladder cancer: A survey by the AIRO uro-group.
AIRO
Bladder cancer
Palliative radiotherapy
Survey
Journal
Medical oncology (Northwood, London, England)
ISSN: 1559-131X
Titre abrégé: Med Oncol
Pays: United States
ID NLM: 9435512
Informations de publication
Date de publication:
23 Jan 2021
23 Jan 2021
Historique:
received:
25
11
2020
accepted:
01
01
2021
entrez:
23
1
2021
pubmed:
24
1
2021
medline:
22
9
2021
Statut:
epublish
Résumé
Radiotherapy (RT) is rarely used in the palliative management of muscle-invasive bladder cancer (MIBC). This survey aims to explore current care patterns within the Italian Radiation Oncologist community on this topic. In 2020, the uro-oncological study group of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) conducted a survey evaluating the RT role in advanced MIBC. An electronic questionnaire was administered online to the society members asking for: general considerations, patients' selection, and aim of the treatment, RT schedule and practical consideration, past and future perspective. Sixty-one questionnaires were returned (33% response rate). Most responders (62.30%) declared to work in a Center with a multidisciplinary uro-oncological team, and 8.20% to evaluate more than 20 patients with MIBC/year for palliative RT. Elderly patients were the most frequently evaluated (46.7%) and life expectancy was the most common selection criteria (44.60%). Thirty Gy in 10 fractions (58.9%), whole bladder as GTV (62.5%), PTV isotropic margins of 1.5-2 cm (44.6%) and IMRT/VMAT technique (58.14%) were the most common treatment choices. Patients amenable for bladder palliative RT were most commonly referred by the urologist (43.86%) or the multidisciplinary team (38%). The reported main reasons for the low involvement of radiation oncologist in the management of MIBC patients were low attention to the palliative setting in bladder cancer (37.5%); radiation oncologist not involved in the management of these patients (32.1%); cases not discussed in the multidisciplinary board (26.8%). This survey illustrated the current use of palliative RT for patients with advanced MIBC in Italy and suggested the need for a greater involvement of radiation oncologists in their management.
Identifiants
pubmed: 33484363
doi: 10.1007/s12032-021-01455-4
pii: 10.1007/s12032-021-01455-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
14Références
Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71(1):96–108. https://doi.org/10.1016/j.eururo.2016.06.010 . Epub 2016 Jun 28
doi: 10.1016/j.eururo.2016.06.010
pubmed: 27370177
Ali A, Song YP, Mehta S, Mistry H, Conroy R, Coyle C, Logue J, Tran A, Wylie J, Janjua T, Joseph L, Joseph J, Choudhury A. Palliative radiation therapy in bladder cancer-importance of patient selection: a retrospective multicenter study. Int J Radiat Oncol Biol Phys. 2019;105(2):389–93. https://doi.org/10.1016/j.ijrobp.2019.06.2541 . Epub 2019 Jul 5. PMID: 31283979
doi: 10.1016/j.ijrobp.2019.06.2541
pubmed: 31283979
Linee Guida AIRO-AIRB 2018: Neoplasie della Vescica. Tumori. 2018; 104(2_suppl):S5-S7. https://doi.org/10.1177/0300891618766104 . PMID: 29893173.
Witjes JA, Babjuk M, Bellmunt J, Bruins HM, et al. EAU-ESMO consensus statements on the Management of Advanced and Variant Bladder Cancer-an International Collaborative Multistakeholder Effort†: under the auspices of the EAU-ESMO guidelines committees. Eur Urol. 2020;77(2):223–50. https://doi.org/10.1016/j.eururo.2019.09.035 . Epub 2019 Nov 19. Erratum in: Eur Urol 2020; 78(1):e48–e50. PMID: 31753752
doi: 10.1016/j.eururo.2019.09.035
pubmed: 31753752
Jereczek-Fossa BA, Colombo R, et al. Urinary bladder preservation for muscle-invasive bladder cancer: a survey among radiation oncologists of Lombardy. Italy Tumori. 2015;101(2):174–8. https://doi.org/10.5301/tj.5000235 . Epub 2015 Mar 5. PMID: 25744865
doi: 10.5301/tj.5000235
pubmed: 25744865
Ferrell BR, Temel JS, Temin S, Alesi ER, Balboni TA, Basch EM, Firn JI, Paice JA, Peppercorn JM, Phillips T, Stovall EL, Zimmermann C, Smith TJ. Integration of palliative care into standard oncology care: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2017;35(1):96–112. https://doi.org/10.1200/JCO.2016.70.1474 . Epub 2016 Oct 28. PMID: 28034065
doi: 10.1200/JCO.2016.70.1474
pubmed: 28034065
Hugar LA, Lopa SH, Yabes JG, Yu JA, Turner RM 2nd, Fam MM, MacLeod LC, Davies BJ, Smith AB, Jacobs BL. Palliative care use amongst patients with bladder cancer. BJU Int. 2019;123(6):968–75. https://doi.org/10.1111/bju.14708 . Epub 2019 Mar 12. PMID: 30758125
doi: 10.1111/bju.14708
pubmed: 30758125
Duchesne GM, Bolger JJ, Griffiths GO, Trevor Roberts J, Graham JD, Hoskin PJ, Fossâ SD, Uscinska BM, Parmar MK. A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: results of medical research council trial BA09. Int J Radiat Oncol Biol Phys. 2000;47(2):379–88. https://doi.org/10.1016/s0360-3016(00)00430-2 . PMID: 10802363
doi: 10.1016/s0360-3016(00)00430-2
pubmed: 10802363
John JB, Varughese MA, Cooper N, Wong K, Hounsome L, Treece S, McGrath JS, Harden S. Treatment Allocation and Survival in Patients Diagnosed with Nonmetastatic Muscle-invasive Bladder Cancer: An Analysis of a National Patient Cohort in England. Eur Urol Focus. 2020;19:S2405-4569(20)30032-8. https://doi.org/10.1016/j.euf.2020.01.013 . Epub ahead of print. PMID: 32088138
doi: 10.1016/j.euf.2020.01.013
Khor RC, Bressel M, Tedesco J, Tai KH, Ball DL, Duchesne GM, Farrugia H, Yip WK, Foroudi F. Tolerability and outcomes of curative radiotherapy in patients aged 85 or more years. Med J Aust. 2015;202(3):153–5. https://doi.org/10.5694/mja14.00441 . PMID: 25669479
doi: 10.5694/mja14.00441
pubmed: 25669479
Lutkenhaus LJ, van Os RM, Bel A, Hulshof MC. Clinical results of conformal versus intensity-modulated radiotherapy using a focal simultaneous boost for muscle-invasive bladder cancer in elderly or medically unfit patients. Radiat Oncol. 2016;11:45. https://doi.org/10.1186/s13014-016-0618-6 . PMID: 26993980; PMCID: PMC4797227
doi: 10.1186/s13014-016-0618-6
pubmed: 26993980
pmcid: 4797227
Jereczek-Fossa BA, Marvaso G. Palliative radiation therapy in bladder cancer: a matter of dose, techniques and patients’ selection. Ann Palliat Med. 2019;8(5):786–9. https://doi.org/10.21037/apm.2019.11.02 . PMID: 31865738
doi: 10.21037/apm.2019.11.02
pubmed: 31865738
Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, Shank B, Solin LJ, Wesson M. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21(1):109–22. https://doi.org/10.1016/0360-3016(91)90171-y . PMID: 2032882
doi: 10.1016/0360-3016(91)90171-y
pubmed: 2032882